slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
220,771-220,800 of 319,975
34
Freightos | Investor Presentation Deck | 34 slidesFreightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
01
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations 1 hit
02
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations 1 hit
03
The slide uses a five-column layout to present key investment pillars.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Problem1 hit
04
The slide title mentions 4 key messages, but only 2 are presented on this page.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Problem1 hit
05
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Problem1 hit
06
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Solution1 hit
07
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Solution1 hit
08
The slide uses a structured approach to justify a capital allocation decision based on external regulatory environments.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · SolutionLoop · Why Now1 hit
09
CQP likely refers to Customer Qualification Process; FID refers to Final Investment Decision; SOP refers to Start of Production.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · SolutionLoop · Why Now1 hit
10
The slide uses a two-column layout to contrast the 'why' (rationale) and the 'how/when' (status) of a corporate action.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
11
The slide uses a waterfall chart to explain the cash position change.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Financials1 hit
13
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · The Ask1 hit
14
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · The Ask1 hit
01
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
02
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
03
The slide uses a combination of bulleted benefits and a visual process diagram to explain the mechanism of action.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
04
The slide uses a linear process flow to highlight competitive differentiation.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
05
The slide uses a Gantt-style visualization to represent drug development stages.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
06
The slide emphasizes vertical integration and strategic supply agreements as a moat.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
07
Includes a logo grid of previous affiliations at the bottom.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
08
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Includes a visual case study (Subject #4) showing PET scan response.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Includes a clinical case study image showing patient response to therapy.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market Opportunity1 hit
11
The slide illustrates the transition from a 177Lu-based molecule (IPN-1087) to a 225Ac-based molecule (FPI-2059) to improve efficacy.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market Opportunity1 hit
12
The slide outlines a standard clinical trial dose escalation design (3+3) for a radiopharmaceutical.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market Opportunity1 hit
13
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
14
The slide contrasts a chemotherapy-based approach (SMDC) with a radioligand therapy (RLT) approach, highlighting the superior PSA response in the RLT cohort.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
15
The slide uses a PET scan image to demonstrate selective tumor uptake versus normal tissue, and a table to quantify market opportunity by tumor type.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit